Raymond A. Kempf

Active specific immunotherapy for melanoma: phase I trial of allogeneic lysates and a novel adjuvant.

M S Mitchell, June Kan‐Mitchell, Raymond A. Kempf et al. · PubMed · 1988 · 237 citations

Immunology, Immunotherapeutics, Dermatology +18

Adjuvant Immunotherapy of Resected, Intermediate-Thickness, Node-Negative Melanoma With an Allogeneic Tumor Vaccine: Overall Results of a Randomized Trial of the Southwest Oncology Group

Vernon K. Sondak, P. Y. Liu, Ralph J. Tuthill et al. · Journal of Clinical Oncology · 2002 · 222 citations

Adjuvant Immunotherapy of Resected, Intermediate-Thickness, Node-Negative Melanoma With an Allogeneic Tumor Vaccine: Impact of HLA Class I Antigen Expression on Outcome

Jeffrey A. Sosman, Joseph M. Unger, P. Y. Liu et al. · Journal of Clinical Oncology · 2002 · 206 citations

Effectiveness and tolerability of low-dose cyclophosphamide and low-dose intravenous interleukin-2 in disseminated melanoma [corrected].

M S Mitchell, Raymond A. Kempf, W. Harel et al. · Journal of Clinical Oncology · 1988 · 197 citations

Low-dose Intravenous Interleukin-2, Low-dose Cyclophosphamide, Medicine +12

Active-specific immunotherapy for melanoma.

M S Mitchell, W. Harel, Raymond A. Kempf et al. · Journal of Clinical Oncology · 1990 · 184 citations

Active-specific Immunotherapy, Tumor Immunology, Surgical Oncology +15